Treatment of periorbital edema with human corticotropin-releasing factor after blepharoplasty.

BACKGROUND

This prospective study of 32 patients was undertaken to ev evaluate the formation of postoperative periorbital edema after administration of human corticotropin-releasing factor (hCRF). Human corticotropin-releasing factor has strong antiedematous properties as a result of direct action on blood vessels independent of endocrine function and has been shown to have a positive effect on vascular permeability in animal studies independent of corticosteroid effects.

STUDY

DESIGN

Human corticotropin-releasing factor was administered intravenously preoperatively to patients undergoing blepharoplasty in doses of 2, 4, and 8 mu g/kg body weight as a randomized, double-blind, placebo-controlled study. The periorbital edema was measured by the use of a three-dimensional laser scanner to determine facial and eyelid volume changes as specified times postoperatively.

RESULTS

Human corticotropin-releasing factor was well tolerated when administered intravenously over a ten-minute period to healthy patients undergoing blepharoplasty. Mild transitory flushing and hypotension were the most common adverse events. Transient decreases in systolic and diastolic blood pressure and increases in heart rate occurred at hCRF doses greater than 2 mu g/kg and were most prominent at 8 mu g/kg. The 8 mu g/kg hCRF dose also showed a trend toward less postoperative edema but this was not statistically significant at the p<0.05 level.

CONCLUSIONS

Human corticotropin-releasing factor appears to be safe for intravenous use in patients undergoing blepharoplasty; however, its efficacy in reducing postoperative edema as a single preoperative administration was not conclusively demonstrated in this study. Further research with a larger study population and other dosing regimens is indicated.